NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
Bayer
Hoffmann-La Roche
Alume Biosciences, Inc.
Hoffmann-La Roche
Icahn School of Medicine at Mount Sinai
NRG Oncology
Hoffmann-La Roche
AstraZeneca
AstraZeneca
Resilience
Astellas Pharma Inc
Canadian Cancer Trials Group
AstraZeneca